Janice Lu

Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial

François‐Clément Bidard, Virginia Kaklamani, Patrick Neven et al. · Journal of Clinical Oncology · 2022 · 626 citations · Full text

Phase II Randomized Study of Trastuzumab Emtansine Versus Trastuzumab Plus Docetaxel in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer

Sara A. Hurvitz, Luc Dirix, Judit Kocsis et al. · Journal of Clinical Oncology · 2013 · 389 citations

Association of Event-Free and Distant Recurrence–Free Survival With Individual-Level Pathologic Complete Response in Neoadjuvant Treatment of Stages 2 and 3 Breast Cancer

Douglas Yee, Angela DeMichele, Christina Yau et al. · JAMA Oncology · 2020 · 207 citations · Full text

Isolation of circulating epithelial and tumor progenitor cells with an invasive phenotype from breast cancer patients

Janice Lu, Tina Fan, Qiang Zhao et al. · International Journal of Cancer · 2009 · 149 citations · Full text

Breast Oncology, Biological Microenvironments, Pathology +20

Circulating Tumor Cells Exhibit Metastatic Tropism and Reveal Brain Metastasis Drivers

Rémi Klotz, Amal Thomas, Teng Teng et al. · Cancer Discovery · 2019 · 136 citations · Full text